Medically reviewed by Sanja Jelic, MD Key Takeaways Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler.Before using Symbicort, tell your healthcare ...

The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide and ...

Wilmington, DE – May 20, 2008 – A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT® (budesonide ...

(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...

Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...

Iconovo, which develops complete inhalation products for a global market, is expanding its collaboration with Amneal for Symbicort in the ICOres inhaler to include additional territories with a ...

Mylan's proposed generic version of AstraZeneca's billion-dollar asthma drug gets another shot in patent case Lower court misinterpreted patents' terms, said divided Federal Circuit (Reuters) - Mylan ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...

AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced approval of the first generic of Symbicort — budesonide and formoterol fumarate dihydrate — ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...